Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

American Journal of Human Genetics

Volumn 78, Issue 5, 2006, Pages 804-814

  McMahon, Francis J ^a   Buervenich, Silvia ^a   Charney, Dennis ^b   Lipsky, Robert ^c   Rush, A John ^d   Wilson, Alexander F ^e   Sorant, Alexa J M ^e   Papanicolaou, George J ^e   Laje, Gonzalo ^a   Fava, Maurizio ^f   Trivedi, Madhukar H ^d   Wisniewski, Stephen R ^g   Manji, Husseini ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN 2A RECEPTOR;

ADULT; ALLELE; ARTICLE; DEPRESSION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RECEPTOR DOWN REGULATION; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 33646062299     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/503820     Document Type: Article

References (53)

1. Cassano P, Fava M (2002) Depression and public health: an overview. J Psychosom Res 53:849-857
2. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386-392
3. Murray CJ, Lopez AD (1996) Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274:740-743
4. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66:974-981
5. Marangell LB (2001) Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry Suppl 18 62:12-17
6. Serretti A, Artioli P, Quartesan R (2005) Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 15:61-67
7. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R (2002) Treatment approaches to major depressive disorder relapse. Part 2. Reinitiation of antidepressant treatment. Psychother Psychosom 71:195-199
8. Franchini L, Serretti A, Gasperini M, Smeraldi E (1998) Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 32:255-259
9. Remillard AJ, Blackshaw SL, Dangor A (1994) Differential responses to a single antidepressant in recurrent episodes of major depression. Hosp Community Psychiatry 45:359-361
10. Stern SL, Rush AJ, Mendels J (1980) Toward a rational pharmacotherapy of depression. Am J Psychiatry 137:545-552
11. Malhotra AK, Murphy GM Jr, Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796
12. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28-40
13. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119-142
14. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
15. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296
16. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Association, Washington, DC
17. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003) The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573-583
18. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM (2004) The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34:73-82
19. Cassano P, Fava M (2004) Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 16:15-25
20. The International HapMap Consortium (2003) The International HapMap Project. Nature 426:789-796
21. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106-120
22. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, et al (2004) Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319-1325
23. Hahn MK, Mazei-Robison MS, Blakely RD (2005) Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol Pharmacol 68:457-466
24. Gunderson KL, Kruglyak S, Graige MS, Garcia F, Kermani BG, Zhao C, Che D, Dickinson T, Wickham E, Bierle J, Doucet D, Milewski M, Yang R, Siegmund C, Haas J, Zhou L, Oliphant A, Fan JB, Barnard S, Chee MS (2004) Decoding randomly ordered DNA arrays. Genome Res 14:870-877
25. Kraemer HC, Thiemann S (1987) How many subjects? Statistical power analysis in research. Sage Publications, London
26. Gauderman WJ (2002) Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155:478-484
27. Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using miiltilocus genotype data. Genetics 155:945-959
28. Boehnke M, Cox NJ (1997) Accurate inference of relationships in sib-pair linkage studies. Am J Hum Genet 61:423-429
29. Wittke-Thompson JK, Pluzhnikov A, Cox NJ (2005) Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 76:967-986
30. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
31. Bray NJ, Buckland PR, Hall H, Owen MJ, O'Donovan MC (2004) The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol Psychiatry 9:109-114
32. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen K, Shih JC, Knapp M, Propping P, Nothen MM (1996) Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 97:614-619
33. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ (2004) The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 56:406-410
34. Jaeschke R, Guyatt G, Barratt A, Walter S, Cook D, McAlister F, Attia J (2002) Measures of association. In: Gyuatt G, Rennie D (eds) User's guides to the medical literature: a manual of evidence-based clinical practice. AMA Publications, Chicago, pp 351-368
35. Anguelova M, Benkelfat C, Turecki G (2003) A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter. I. Affective disorders. Mol Psychiatry 8:574-591
36. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38:209-213
37. Brown C, Schulberg HC, Sacco D, Perel JM, Houck PR (1999) Effectiveness of treatments for major depression in primary medical care practice: a post hoc analysis of outcomes for African American and white patients. J Affect Disord 53:185-192
38. Norton N, Owen MJ (2005) HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 37:121-129
39. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP (2004) Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 9:879-889
40. Choi MJ, Kang RH, Ham BJ, Jeong HY, Lee MS (2005) Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 52:155-162
41. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R, Lorenzi C, Smeraldi E (2002) Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 5:27-35
42. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B (2001) Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 303:119-122
43. Leysen JE (2004) 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3:11-26
44. Mann JJ, Curreier D, Quiroz JA, Manji HK (2005) Neurobiology of severe mood and anxiety disorders. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds) Basic Neurochemistry. Lippincott-Raven, New York, pp 887-911
45. Humphrey PP, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233-236
46. Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813-829
47. Manji HK, Drevets WC, Charney DS (2001) The cellular neurobiology of depression. Nat Med 7:541-547
48. Peremans K, Audenaert K, Hoybergs Y, Otte A, Goethals I, Gielen I, Blankaert P, Vervaet M, van Heeringen C, Dierckx R (2005) The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with 123I-5-I-R91150 SPECT. Eur J Nucl Med Mol Imaging 32:708-716
49. Strome EM, Clark CM, Zis AP, Doudet DJ (2005) Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: an in vivo positron emission tomography study with [18F]setoperone. Biol Psychiatry 57:1004-1010
50. Papolos DF, Yu YM, Rosenbaum E, Lachman HM (1996) Modulation of learned helplessness by 5-hydroxytryptamine2A receptor antisense oligodeoxynucleotides. Psychiatry Res 63:197-203
51. Coyle JT, Duman RS (2003) Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38:157-160
52. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13-25
53. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17:2785-2795